



News Release

HYDERABAD, INDIA (8 Aug 2023) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 30 June 2023. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 8 Aug 2023 at Hyderabad.

	CONSOLIDATED STATEMENT OF OPERATIONS			
	<i>INR Million, except EPS</i>			
	Quarter ended			Year ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
<i>Revenue</i>	94.37	82.13	39.75	219.88
R&D and Operational expenses	318.12	341.32	246.18	1,394.24
Depreciation and Amortisation	16.65	16.72	15.81	65.43
Finance cost	0.51	0.54	1.02	2.89
<i>Total expenses</i>	335.27	358.58	263.01	1,462.56
<i>Profit/(Loss) Before exceptional items</i>	(240.91)	(276.45)	(223.26)	(1,242.68)
Exceptional items	-	-	60.00	60.00
Other comprehensive income	0.48	3.03	(0.38)	1.90
<i>Total comprehensive income</i>	(240.43)	(273.42)	(163.64)	(1,180.78)
Paid up equity capital	218.07	218.07	145.38	218.07
<i>Consolidated earnings per share of Rs.1 each</i>	(1.10)	(1.17)	(1.12)	(6.63)

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) Clinical development pipeline:
- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of 2025.
 - SUVN-G3031 (Samelisant) – Closed phase 2 study on Narcolepsy in North America; expected results of outcome by Sep/Oct 2023.
 - SUVN-911 (Ropanicant) – Completed phase 1 study, ready for initiating phase 2 study.
 - SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2 study.
- (d) Since last reporting period, the Company has been granted 5 patents for its innovative drug discovery covering, ARIPO, Brazil and USA.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com